Playtika resumed with a Neutral at Citi

Citi resumed coverage of Playtika with a Neutral rating and $11 price target. The analyst sees continued upside from future acquisitions, but also potential risks from payer conversion rates falling from pandemic-highs. As such, the firm continues to view Playtika’s risk/reward as relatively balanced at current levels.